Title: Global Atopic Dermatitis Drugs Market | Trends, Analysis, Forecast 2019-2027
1Atopic Dermatitis Market
FORECAST 2019-2027
2(No Transcript)
3- The Atopic Dermatitis Drugs global market is
growing at 4.66 of CAGR over the forecasting
years. - Growing incidences of allergies due to particular
foods is the major factor augmenting the market
growth globally.
4- Atopic Dermatitis is a skin disease also known as
chronic eczematous. The symptoms of this disease
vary person to person. However, some of its
common symptoms are inflamed and itchy skin that
causes crackling, minute blisters, swelling,
scaling, and crusting. - The global Atopic Dermatitis drugs market
comprise of two segments route of administration
and drug class. - The topical segment holds the highest share in
the Atopic Dermatitis Drugs route of
administration market. - The interleukin inhibitor segment is anticipated
to generate the highest revenue in the Atopic
Dermatitis drug class market. - The global Atopic Dermatitis Drugs market is
highly generic which creates a lot of challenges
in the growth of the market globally.
5(No Transcript)
6The Atopic Dermatitis Drugs global market is
growing at 4.66 of CAGR over the forecasting
years.
7During the forecasting years, the Atopic
Dermatitis Drugs market in North America is
proliferating at a CAGR of 4.06.
8Europe Atopic dermatitis drugs market continues
to escalate at 3.20 of CAGR over the forecasting
years.
9The Atopic Dermatitis Drugs market in APAC region
is anticipated to evolve at a CAGR of 7.46 over
the estimated period 2018-2026.
10The established players in the market are
Allergan Plc., Aqua Pharmaceuticals (An Almirall
Company), Astellas Pharma Inc., Bayer Ag,
Biofrontera Ag, Bristol-Myers Squibb, Stiefel
Laboratories Inc., Encore Dermatology, Galderma
Sa, Leo Pharma, Meda Pharmaceuticals (Mylan),
Novartis Ag, Pfizer, Regeneron Pharmaceuticals,
Sanofi Sa, and Valent Pharmaceutical Inc.
11(No Transcript)
12(No Transcript)
13(No Transcript)